{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:11Z","timestamp":1791397391878,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejmech.2022.114249","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:23:26Z","timestamp":1646220206000},"page":"114249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible\/irreversible pan-HER inhibitors"],"prefix":"10.1016","volume":"233","author":[{"given":"Qidong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjiang","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114249_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114249_bib2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/anie.201710398","article-title":"Lessons to Be learned: the molecular basis of kinase-targeted therapies and drug resistance in non-small cell lung cancer","volume":"57","author":"Lategahn","year":"2018","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2022.114249_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fonc.2015.00002","article-title":"The potential of panHER inhibition in cancer","volume":"5","author":"Wang","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.114249_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114249_bib5","first-page":"11","article-title":"Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)","author":"Cocco","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2022.114249_bib6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41401-018-0176-6","article-title":"Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein","volume":"40","author":"Meng","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114249_bib7","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1541-7786.MCR-19-0419","article-title":"EGFRTAS6417\/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant mutations","volume":"17","author":"Udagawa","year":"2019","journal-title":"Mol. Cancer Res.: MCR"},{"key":"10.1016\/j.ejmech.2022.114249_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41388-020-01564-w","article-title":"Selective inhibition of stemness through EGFR\/FOXA2\/SOX9 axis reduces pancreatic cancer metastasis","volume":"40","author":"Kaushik","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114249_bib9","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.cllc.2016.09.006","article-title":"Therapeutic efficacy comparison of 5 major EGFR-TKIs in advanced EGFR-positive non-small-cell lung cancer: a network meta-analysis based on head-to-head trials","volume":"18","author":"Zhang","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ejmech.2022.114249_bib10","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ejmech.2022.114249_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2019.02.008","article-title":"Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension","volume":"850","author":"Yu","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114249_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200811-1682OC","article-title":"Role of epidermal growth factor inhibition in experimental pulmonary hypertension","volume":"181","author":"Dahal","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2022.114249_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1756-8722-7-22","article-title":"A\u00a0phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors","volume":"7","author":"Zhang","year":"2014","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114249_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114249_bib15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ijc.32188","volume":"145","author":"Kim","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114249_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1039\/C6MD00463F","article-title":"Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib","volume":"8","author":"von Manstein","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2022.114249_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010105","article-title":"Varlitinib downregulates HER\/ERK signaling and induces apoptosis in triple negative breast cancer cells","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114249_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3347\/kjp.2017.55.5.491","article-title":"Suppressors for human epidermal growth factor receptor 2\/4 (HER2\/4): a new family of anti-toxoplasmic agents in ARPE-19 cells","volume":"55","author":"Kim","year":"2017","journal-title":"Kor. J. Parasitol."},{"key":"10.1016\/j.ejmech.2022.114249_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10549-016-3979-5","article-title":"Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: phase II randomized study in women with endocrine-therapy-na\u00efve advanced breast cancer","volume":"160","author":"Johnston","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2022.114249_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejmech.2019.03.004","article-title":"Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry","volume":"170","author":"Das","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114249_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ctrv.2015.05.011","article-title":"ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis","volume":"41","author":"Van Sebille","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2022.114249_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114249_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021487","article-title":"AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in\u00a0vitro and in\u00a0vivo","volume":"6","author":"Xie","year":"2011","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.ejmech.2022.114249_bib24","doi-asserted-by":"crossref","first-page":"127472","DOI":"10.1016\/j.bmcl.2020.127472","article-title":"Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors","volume":"30","author":"Lee","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114249_bib25","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.bmc.2011.01.055","article-title":"Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates","volume":"19","author":"Marvania","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114249_bib26","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41401-018-0056-0","article-title":"Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R","volume":"39","author":"Liu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114249_bib27","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1021\/acs.jmedchem.1c00690","article-title":"Structure-based optimization of 3-phenyl-N-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide derivatives as selective mcl-1 inhibitors","volume":"64","author":"Li","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114249_bib28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41401-018-0191-7","article-title":"C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis","volume":"40","author":"Chen","year":"2019","journal-title":"Acta Pharmacol. Sin."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:40:23Z","timestamp":1759329623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":28,"alternative-id":["S0223523422001519"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114249","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible\/irreversible pan-HER inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114249"}}